MedTrace Logo

Anti-PD-1/PD-L1 Antibodies Plus S-adenosyl-methionine Treatment in Patients With Advanced-Stage Hepatocellular Carcinoma

NCT05701553 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2023-02-02

No results posted yet for this study

Summary

This study is being done to analyze the safety, tolerability, and efficacy of treatment using combination of SAM and anti-PD-1/PDL1 antibodies for patients with advanced hepatocellular carcinoma.

Conditions

Interventions

DRUG

Anti-PD-1/PD-L1

Intravenous injection at indicated dose for at least 6 months

DRUG

S-Adenosyl-Methionine

Taken orally at indicated dose for at least 6 months

Sponsors & Collaborators

  • Shanghai Zhongshan Hospital

    lead OTHER

Principal Investigators

  • Jia Fan · Fudan University

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-26
Primary Completion
2025-12-31
Completion
2025-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05701553 on ClinicalTrials.gov